MedPage Today on MSN3d
Brain Edema, Imaging Abnormalities Reported for Alzheimer's Drug
Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
‘Miracle’ Alzheimer’s drug ‘triggers deadly brain bleeds in up to a third’, new study finds
AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...
pharmaphorum2d
Five takeaways from the new donanemab data
Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...
pharmaphorum5d
Lilly files Alzheimer's drug donanemab as Cortexyme rival fails trial
Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their ...
Fresh warning over £60K 'miracle' Alzheimer's drug as study finds it could trigger brain bleeds in up to a third
A so-called 'miracle' Alzheimer's drug caused brain bleeds in more than a third of patients, a new study has revealed.
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
Pharmaceutical Technology on MSN4d
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
Vaccinex went public in 2018, raising around $40m to advance its pipeline of neurodegenerative disease therapies. The initial ...